Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20407 publications

Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.

Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.

Journal: Cell transplantation
Published: October 18, 2025

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.

Journal: Future oncology (London, England)
Published: October 13, 2025

Interval Changes in Hematopoietic Vacuolization in VEXAS Syndrome with M41T Mutation: Insights into Diagnosis and Disease Progression.

Interval Changes in Hematopoietic Vacuolization in VEXAS Syndrome with M41T Mutation: Insights into Diagnosis and Disease Progression.

Journal: Clinical laboratory
Published: October 13, 2025

The prognostic impact of chromosome 7 with both arms loss [der(7)del(7p)del(7q)] in myelodysplastic syndrome/neoplasm.

The prognostic impact of chromosome 7 with both arms loss [der(7)del(7p)del(7q)] in myelodysplastic syndrome/neoplasm.

Journal: Hematology (Amsterdam, Netherlands)
Published: October 13, 2025

Using imetelstat for lower-risk myelodysplastic syndromes.

Using imetelstat for lower-risk myelodysplastic syndromes.

Journal: Clinical advances in hematology & oncology : H&O
Published: October 06, 2025

In low-risk myelodysplastic syndrome, don't shoot the STAG2.

In low-risk myelodysplastic syndrome, don't shoot the STAG2.

Journal: Blood
Published: October 02, 2025

Management of MDS according to risk classifications

Management of MDS according to risk classifications

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 01, 2025

Genetic alterations in myelodysplastic neoplasms of childhood

Genetic alterations in myelodysplastic neoplasms of childhood

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 01, 2025

siRNA Mediated Genetic Perturbation of Primary Human Leukemia Stem and Progenitor Cells.

siRNA Mediated Genetic Perturbation of Primary Human Leukemia Stem and Progenitor Cells.

Journal: bioRxiv : the preprint server for biology
Published: September 26, 2025

Validation and Modeling of Flow Cytometric CD36 Coefficient of Variation (CV) Analysis in the Diagnosis of Lower-Risk Myelodysplastic Syndromes.

Validation and Modeling of Flow Cytometric CD36 Coefficient of Variation (CV) Analysis in the Diagnosis of Lower-Risk Myelodysplastic Syndromes.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology
Published: September 25, 2025

Blood biomarkers and medication response following group psychotherapy as an add-on treatment in refractory idiopathic myelodysplasia.

Blood biomarkers and medication response following group psychotherapy as an add-on treatment in refractory idiopathic myelodysplasia.

Journal: Journal of psychosocial oncology
Published: September 23, 2025

Role of Chromatin Looping Factors in Leukemia.

Role of Chromatin Looping Factors in Leukemia.

Journal: Annual review of pathology
Published: September 15, 2025
Showing 1-12 of 20,407

Last Updated: 10/31/2025